Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Alzheimer’s Disease

  • Chapter
  • First Online:
Metabolism of Human Diseases

  • 171k Accesses

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder and the leading cause of dementia in the elderly. It is predicted that by 2050 over 13 million people in the United States will have AD dementia [1]. AD has an immense socioeconomic impact on patients, families, and caregivers and is a huge burden to the health-care system as the cost of care for AD and other dementias is expected to increase from an estimated $203 billion in 2013 to a projected $1.2 trillion per year by 2050 [2]. Clinical onset of AD is characterized by initial symptoms of short-term memory loss, which worsens gradually and is accompanied by language disturbances, apathy, and impairments in executive function and daily functioning. Neuropsychiatric symptoms (e.g., depression, anxiety, hallucinations) are frequent in mid- to late stages.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80:1778–1783

    Article  PubMed  PubMed Central  Google Scholar 

  2. Alzheimer’s Association’s (2013) Alzheimer’s disease facts and figures report. www.alz.org/downloads/facts_figures_2013.pdf. As available on 18 Aug 2013

  3. Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 64:146–148

    Google Scholar 

  4. Maurer K, Volk S, Gerbaldo H (1997) Auguste D and Alzheimer’s disease. Lancet 349:1546–1549

    Article  CAS  PubMed  Google Scholar 

  5. Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5(3–4):118–121

    Article  CAS  PubMed  Google Scholar 

  6. Arendt T (2009) Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol 118:167–179

    Article  PubMed  Google Scholar 

  7. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RA, Chui HC, Knopman DS, Reeder TM, Shetter AG, Senter HJ, Markesbery WR (1992) Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 32:625–632

    Article  CAS  PubMed  Google Scholar 

  8. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC (2013) Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology 80:648–654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2. pii:a006296

    Google Scholar 

  10. Jack CRJ, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 11:1048–1056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185

    Article  CAS  PubMed  Google Scholar 

  13. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615–29619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Steiner H, Capell A, Leimer U, Haass C (1999) Genes and mechanisms involved in beta-amyloid generation and Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 249:266–270

    Article  CAS  PubMed  Google Scholar 

  15. Braak H, Del Tredici K (2011) Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121:589–595

    Article  CAS  PubMed  Google Scholar 

  16. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697

    Article  PubMed  PubMed Central  Google Scholar 

  17. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7:e31302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33:1024–1037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Martinez R, de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372

    Article  CAS  PubMed  Google Scholar 

  20. Jack CRJ, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:257–262

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292

    Article  PubMed  PubMed Central  Google Scholar 

  22. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300:2253–2262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, Dombroski BA, Crane PK, Larson EB, Alzheimer’s Disease Genetics Consortium, Mayeux R, Haines JL, Lunetta KL, Pericak-Vance MA, Schellenberg GD, Farrer LA (2012) Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol 69:1270–1279

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine and Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, 200 Lothrop Street, BSTWR-S521, Pittsburgh, PA, 15213, USA

    Milos D. Ikonomovic

  2. Department of Neurology, University of Virginia School of Medicine, 800793, Charlottesville, VA, 22908, USA

    Steven T. DeKosky

Authors
  1. Milos D. Ikonomovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven T. DeKosky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven T. DeKosky .

Editor information

Editors and Affiliations

  1. Institute of Metabolic Physiology, German Diabetes Center, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    Eckhard Lammert

  2. CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

    Martin Zeeb

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Ikonomovic, M.D., DeKosky, S.T. (2014). Alzheimer’s Disease. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_7

Download citation

Publish with us

Policies and ethics

Search

Navigation